Calvaruso V, et al. - Researchers assessed the occurrence rate of hepatocellular carcinoma (HCC) in patients with hepatitis C virus (HCV)-associated cirrhosis treated with direct-acting antivirals (DAAs) from March 2015 through July 2016 at 22 academic and community liver centers in Sicily, Italy. Findings revealed the mean interval in time from DAA exposure to an HCC diagnosis was 9.8 months and did not vary prominently between patients with and without a sustained virologic response (SVR). It was discovered that SVR to DAA treatment reduced the incidence of HCC over a mean follow-up of 14 months.